ABSTRACT
Abstract Purpose: To establish a new rat model, the pathogenesis of which is closer to the clinical occurrence of chronic obstructive jaundice with liver fibrosis. Methods: 90 SD rats were randomly divided into 3 groups. Group A common bile duct ligation, group B common bile duct injection compont and group C injection saline. The serum of three groups was extracted, and the liver function was detected by ELISA. HE staining, Masson staining and immunohistochemistry were used to detect liver pathology. Results: Group B showed a fluctuant development of jaundice, obstructive degree reached a peak at 2 weeks, and decreased from 3 weeks. HA, LA and PCIII were significantly higher than control group. 3 weeks after surgery, liver tissue fibrosis occurred in group B, and a wide range of fiber spacing was formed at 5 weeks. Immunohistochemistry showed that hepatic stellate cells were more active than the control group. Conclusion: Intra-biliary injection of Compont gel is different from the classic obstructive jaundice animal model caused by classic bile duct ligation, which can provide an ideal rat model of chronic obstructive jaundice with liver fibrosis.
Subject(s)
Animals , Female , Bile Ducts/drug effects , Disease Models, Animal , Gels/administration & dosage , Liver Cirrhosis/chemically induced , Aspartate Aminotransferases/blood , Reference Values , Azo Compounds , Time Factors , Bile Ducts/pathology , Bilirubin/analysis , Serum Albumin/analysis , Enzyme-Linked Immunosorbent Assay , Immunohistochemistry , Random Allocation , Reproducibility of Results , Rats, Sprague-Dawley , Eosine Yellowish-(YS) , Jaundice, Obstructive/chemically induced , Jaundice, Obstructive/pathology , Alkaline Phosphatase/blood , gamma-Glutamyltransferase/blood , Injections , Liver Cirrhosis/pathology , Methyl GreenABSTRACT
OBJECTIVE: The aim of this study was to evaluate the effect of oral tamoxifen treatment on the number of myofibroblasts present during the healing process after experimental bile duct injury. METHODS: The sample consisted of 16 pigs that were divided into two groups (the control and study groups). Incisions and suturing of the bile ducts were performed in the two groups. Tamoxifen (20 mg/day) was administered only to the study group. The animals were sacrificed after 30 days. Quantification of myofibroblasts in the biliary ducts was made through immunohistochemistry analysis using anti-alpha smooth muscle actin of the smooth muscle antibody. Immunohistochemical quantification was performed using a digital image system. RESULTS: In the animals treated with tamoxifen (20 mg/day), there was a significant reduction in immunostaining for alpha smooth muscle actin compared with the control group (0.1155 vs. 0.2021, p = 0.046). CONCLUSION: Tamoxifen reduced the expression of alpha smooth muscle actin in the healing tissue after bile duct injury, suggesting a decrease in myofibroblasts in the scarred area of the pig biliary tract. These data suggest that tamoxifen could be used in the prevention of biliary tract stenosis after bile duct surgeries.
Subject(s)
Animals , Female , Bile Ducts/injuries , Estrogen Antagonists/therapeutic use , Myofibroblasts/drug effects , Tamoxifen/therapeutic use , Wound Healing/drug effects , Actins/analysis , Actins/drug effects , Bile Ducts/drug effects , Cell Count , Immunohistochemistry , Muscle, Smooth/chemistry , Muscle, Smooth/drug effects , Reproducibility of Results , Swine , Treatment OutcomeABSTRACT
Combined pills have known adverse effects on liver function. Progesterone based contraceptives are thought to be safer in this regard. The effect of Norplant, a levonorgestrel contraceptive implant, on liver function was evaluated in 149 Bangladeshi women of reproductive age in this study. Liver function tests and ultrasonography of hepato-biliary system were done before and after the implantation. The patients were followed upto two years. There were non-significant transient rise of serum bilirubin and slight enlargement of liver during the first year. There was no significant change in the levels of AST, ALT, alkaline phosphatase, total protein, albumin-globulin ratio and prothrombin time. The results suggest that Norplant has no adverse effect on liver function.
Subject(s)
Adolescent , Adult , Alanine Transaminase/blood , Alkaline Phosphatase/blood , Aspartate Aminotransferases/blood , Bile Ducts/drug effects , Bilirubin/blood , Blood Proteins/analysis , Contraceptive Agents, Female/administration & dosage , Drug Implants , Evaluation Studies as Topic , Female , Follow-Up Studies , Humans , Hypertrophy , Levonorgestrel/administration & dosage , Liver/drug effects , Progesterone Congeners/administration & dosage , Prothrombin Time , Serum Albumin/analysis , Serum Globulins/analysisABSTRACT
Mujer de 47 años de edad, con regulares hábitos higiénicos-dietéticos. Menarca a los 15 años, GVI, PV, Ci; último parto hacía 8 años; fecha de la última menstruación 1o. de julio de 1982. A los 24 años de edad se le transfundió sangre después de una cesárea. En 1979 presentó neumonía lobar aguda e ictericia; fue tratada con eritromicina por ser alérgica a la penicilina. Desde 1980 se refirió elevación de las bilirrubinas séricas y bilirrubinas. En 1981 recibió HAIN, etambutol y estreptomicina por tener tos y una radiografía de tórax compatible con tuberculosis pulmonar. En 1982 se estableció el diagnóstico de probable síndrome de Sjögren